Have a feature idea you'd love to see implemented?
Let us know!
PCRX Pacira BioSciences Inc
Price (delayed)
$17.02
Market cap
$785.08M
P/E Ratio
12.42
Dividend/share
N/A
EPS
$1.37
Enterprise value
$1.19B
Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local
Highlights
The company's quick ratio has surged by 87% YoY and by 20% QoQ
PCRX's P/E is 83% below its last 4 quarters average of 74.1
Pacira BioSciences's debt has increased by 11% from the previous quarter and by 4.5% YoY
Pacira BioSciences's EPS has decreased by 10% QoQ
Key stats
What are the main financial stats of PCRX
Market
Valuations
Earnings
Shares outstanding
46.13M
Market cap
$785.08M
Enterprise value
$1.19B
Price to earnings (P/E)
12.42
Price to book (P/B)
0.9
Price to sales (P/S)
1.14
EV/EBIT
10.35
EV/EBITDA
6.28
EV/Sales
1.72
Revenue
$690.31M
EBIT
$114.6M
EBITDA
$188.8M
Free cash flow
$184.74M
Per share
Balance sheet
Liquidity
EPS
$1.37
Free cash flow per share
$4
Book value per share
$18.89
Revenue per share
$14.95
TBVPS
$22.28
Total assets
$1.65B
Total liabilities
$767.54M
Debt
$648.6M
Equity
$879.28M
Working capital
$539.52M
Debt to equity
0.74
Current ratio
6.82
Quick ratio
5.49
Net debt/EBITDA
2.13
Margins
Efficiency
Dividend
EBITDA margin
27.4%
Gross margin
74.1%
Net margin
9.2%
Operating margin
13.4%
Return on assets
4%
Return on equity
7.3%
Return on invested capital
8.9%
Return on capital employed
7.4%
Return on sales
16.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PCRX stock price
How has the Pacira BioSciences stock price performed over time
Intraday
-2.07%
1 week
0.41%
1 month
19.35%
1 year
-39.69%
YTD
-49.56%
QTD
13.09%
Financial performance
How have Pacira BioSciences's revenue and profit performed over time
Revenue
$690.31M
Gross profit
$511.19M
Operating income
$92.34M
Net income
$63.59M
Gross margin
74.1%
Net margin
9.2%
The company's operating income has surged by 92% YoY but it fell by 11% QoQ
PCRX's operating margin has soared by 86% YoY but it is down by 12% QoQ
Pacira BioSciences's gross profit has increased by 11% YoY and by 2.5% QoQ
Pacira BioSciences's net margin has decreased by 11% from the previous quarter
Growth
What is Pacira BioSciences's growth rate over time
Valuation
What is Pacira BioSciences stock price valuation
P/E
12.42
P/B
0.9
P/S
1.14
EV/EBIT
10.35
EV/EBITDA
6.28
EV/Sales
1.72
PCRX's P/E is 83% below its last 4 quarters average of 74.1
Pacira BioSciences's EPS has decreased by 10% QoQ
PCRX's P/B is 74% below its 5-year quarterly average of 3.4 and 44% below its last 4 quarters average of 1.6
The equity has increased by 9% year-on-year
The price to sales (P/S) is 72% lower than the 5-year quarterly average of 4.1 and 46% lower than the last 4 quarters average of 2.1
The revenue has grown by 3.2% YoY
Efficiency
How efficient is Pacira BioSciences business performance
PCRX's ROE is down by 12% since the previous quarter
Pacira BioSciences's ROA has decreased by 11% from the previous quarter
Pacira BioSciences's ROIC has decreased by 2.2% from the previous quarter
Pacira BioSciences's return on sales has decreased by 2.4% QoQ
Dividends
What is PCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PCRX.
Financial health
How did Pacira BioSciences financials performed over time
The total assets is 115% greater than the total liabilities
The company's quick ratio has surged by 87% YoY and by 20% QoQ
The current ratio has soared by 73% YoY and by 17% from the previous quarter
Pacira BioSciences's debt is 26% less than its equity
Pacira BioSciences's debt to equity has increased by 14% from the previous quarter but it has decreased by 3.9% YoY
Pacira BioSciences's debt has increased by 11% from the previous quarter and by 4.5% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.